Phosphate binders, cardiovascular calcifications and mortality: Do we need another survival study with sevelamer?

Journal of Nephrology

Volumn 23, Issue 6, 2010, Pages 653-657

  Negri, Armando Luis ^a  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

Author keywords

Cardiovascular mortality; Chronic renal failure; Phosphate; Sevelamer; Vascular calcifications

Indexed keywords

ATORVASTATIN; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; SEVELAMER;

AORTA DISEASE; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HOSPITALIZATION; HUMAN; HYPERPHOSPHATEMIA; KIDNEY CALCIFICATION; MORTALITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; CHELATING AGENTS; HOSPITALIZATION; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MUSCLE, SMOOTH, VASCULAR; PHOSPHATES; POLYAMINES; RENAL DIALYSIS;

EID: 78549263404     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
2. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
3. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate J Am Soc Nephrol. 2003;14(Suppl 4):S300-S304.
4. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75:890-897.
5. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-2867.
6. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 2003;64:1653-1661.
7. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int. 2003;64:441-450. (Pubitemid 36871915)
8. Phan O, Ivanovski O, Nikolov IG, et al. Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant. 2008;23:82-90.
9. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
10. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1489-1496. (Pubitemid 38786743)
11. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19:1827-1835.
12. Morosetti M, Jankovic L, Palombo G, et al. High-dose calcitriol therapy and progression of cardiac vascular calcifications. J Nephrol. 2008;21:603-608.
13. Chertow GM, Burke SK, Raggi. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62:245-252.
14. Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate: phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62:104-115. (Pubitemid 39162762)
15. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815-1824.
16. Qunibi WY, Moustafa M, Kessler P, et al; CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.. Am J Kidney Dis. 2008;51:952-965. (Pubitemid 351697566)
17. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248
18. Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
19. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them. Nephrol Dial Transplant. 2008,23:3050-3052.
20. Barreto DV, Barreto F de C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification: results from the BRiC study. Nephron Clin Pract. 2008;110:c273-c283.
21. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879-885. (Pubitemid 46762749)
22. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival. J Am Soc Nephrol. 2009;20:388-396.
23. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438-441.
24. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130-1137. (Pubitemid 47609037)
25. St Peter WL, Liu j, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445-454.
26. Tonelli M, Wiebe N, Culleton B, et al; Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007;22:2856-2866.
27. Manns B, Klarnbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22:2867-2878. (Pubitemid 350093448)
28. McBride R. After Renvela filing, Genzyme renews focus on Renagel. Mass High Tech: The Journal of New England Technology. Available at: http://www.masshightech.com/stories/2007/01/15/story13-After-Renvela-filling- Genzyme-renews-focus-on-Renael.html. Accessed March 19, 2010.